Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT06885021
PHASE3

Evaluate the Safety and Efficacy of HDM1002 Tablets in Chinese Overweight and Obese Adults

Sponsor: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

View on ClinicalTrials.gov

Summary

A Phase 3 Trial to Evaluate the Safety and Efficacy of HDM1002 Tablets in Overweight and Obese Adults

Official title: A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Trial to Evaluate the Safety and Efficacy of HDM1002 Tablets in Chinese Overweight and Obese Adults

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

780

Start Date

2025-03-28

Completion Date

2026-06-30

Last Updated

2025-03-19

Healthy Volunteers

No

Interventions

DRUG

HDM1002 200mg, oral, once daily, 52 weeks

HDM1002 200mg, oral, once daily, 52 weeks

DRUG

HDM1002 400mg, oral, once daily, 52 weeks

HDM1002 400mg, oral, once daily, 52 weeks

DRUG

HDM1002 placebo, oral, once daily, 52 weeks

HDM1002 placebo, oral, once daily, 52 weeks